Renovaro Inc. (RENB)
NASDAQ: RENB · Real-Time Price · USD
0.505
+0.002 (0.32%)
Nov 21, 2024, 1:46 PM EST - Market open

Company Description

Renovaro Inc., a pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands.

It operates through two segments, RENB and RENC. The company is developing a genetically modified allogeneic dendritic cell therapeutic vaccines, including RENB-DC11 to treat solid tumors primarily for pancreatic tumors; and RENB-DC20 for the treatment of breast cancer.

It also develops an artificial intelligence platform technology for early cancer detection and its recurrence that uses a multi-omics approach to search for individual biomarkers that are present even in asymptomatic patients.

The company was formerly known as Renovaro Biosciences Inc. and changed its name to Renovaro Inc. in February 2024.

Renovaro Inc. is headquartered in Los Angeles, California.

Renovaro Inc.
Renovaro logo
Country United States
Founded 2011
Industry Biotechnology
Sector Healthcare
Employees 25
CEO David Weinstein

Contact Details

Address:
2080 Century Park East, Suite 906
Los Angeles, California 90067
United States
Phone (305) 918-1980
Website renovarobio.com

Stock Details

Ticker Symbol RENB
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001527728
CUSIP Number 236078101
ISIN Number US29350E1047
Employer ID 45-2259340
SIC Code 2834

Key Executives

Name Position
David H. Weinstein Chief Executive Officer and Director
Simon Tarsh Interim Chief Financial Officer
Dr. Francois Binette M.Sc., Ph.D. Chief Operating Officer and Executive Vice President for Research and Development
Dr. Serhat Gümrükcü Co-Founder and Inventor
Greg Duczynski Ph.D. Senior Vice President for Clinical Operations

Latest SEC Filings

Date Type Title
Nov 14, 2024 10-Q Quarterly Report
Nov 8, 2024 8-K Current Report
Nov 6, 2024 EFFECT Notice of Effectiveness
Nov 6, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Oct 30, 2024 S-3 Registration statement under Securities Act of 1933
Oct 29, 2024 8-K/A [Amend] Current report
Oct 28, 2024 10-K/A [Amend] Annual report
Oct 24, 2024 SC 13D/A [Amend] General statement of acquisition of beneficial ownership
Oct 16, 2024 8-K Current Report
Oct 10, 2024 10-K Annual Report